Syntheses of two deacetyl-thymosin alpha(1) analogues and their effects on low E-rosette-forming lymphocytes of uraemic patients.
Abiko. T T; Sekino. H H
Key Findings
- Two deacetyl‑thymosin‑alpha‑1 analogues with a brominated phenylalanine were synthesized
- The analogue with L‑Phe(4Br) improved low E‑rosette‑forming lymphocyte counts in uraemic patients
- The analogue with D‑Phe(4Br) showed no restorative effect
Practical Outcomes
- These results aren’t directly useful for most biohackers because the tested analogues aren’t commercially available and the study focused on a niche patient group. However, it hints that small chemical tweaks can change how thymosin‑alpha‑1 works, suggesting future research might yield more effective versions for broader health applications.
Summary
Researchers made two slightly altered versions of thymosin‑alpha‑1 and tested them on a specific immune cell problem in kidney‑failure patients. One version helped the cells recover better than the regular deacetyl‑thymosin‑alpha‑1, while the other did nothing.
Abstract
Two deacetyl-thymosin alpha(1) analogues containing Phe (4Br) or D-Phe (4Br) residue-[D-Phe(4Br)(21)]deacetyl-thymosin alpha(1) and [Phe(4Br)(21)]deacetyl-thymosin alpha(1), respectively-were synthesized by the manual solid-phase method and their immunological effects on the low E-rosette-forming lymphocytes of uraemic patients were examined. One of the synthetic analogues, [Phe(4Br)(21)deacetyl-thymosin alpha(1), demonstrated a restorative effect on the low E-rosette-forming lymphocytes of uraemic patients, which was stronger than that of deacetyl-thymosin alpha(1), but the other analogue, [D-Phe(4Br)(21)]deacetyl-thymosin alpha(1), showed no restorative effect under the same conditions.
Study Information
pubmed
1996
10.1155/s0962935196000439